GLP-1R agonists promote normal and neoplastic intestinal growth through mechanisms requiring Fgf7.
Cell Metab · 2015
Last updated 2026-05-28In a study on mice, GLP-1 receptor (GLP-1R) signaling was found to control the growth of the small bowel and colon. When treated with the GLP-1 drug exendin-4, mice prone to intestinal tumors had more and larger polyps, but mice lacking the GLP-1R gene had fewer polyps. The drug’s effects depended on a protein called Fgf7, as growth did not increase in mice without it.
AI summary of the abstract below.
| Journal | Cell Metab, 2015 |
|---|---|
| Citations | 118 |
| Relative citation ratio | 3.94 |
| NIH percentile | 89 |
| Molecules | — |
Abstract
Glucagon-like peptide-1 (GLP-1) secreted from enteroendocrine L cells promotes nutrient disposal via the incretin effect. However, the majority of L cells are localized to the distal gut, suggesting additional biological roles for GLP-1. Here, we demonstrate that GLP-1 receptor (GLP-1R) signaling controls mucosal expansion of the small bowel (SB) and colon. These actions did not require the epidermal growth factor (EGF) or intestinal epithelial insulin-like growth factor (IGF1) receptors but were absent in Glp1r(-/-) mice. Polyp number and size were increased in SB of exendin-4-treated Apc(Min/+) mice, whereas polyp number was reduced in SB and colon of Glp1r(-/-):Apc(Min/+) mice. Exendin-4 increased fibroblast growth factor 7 (Fgf7) expression in colonic polyps of Apc(Min/+) mice and failed to increase intestinal growth in mice lacking Fgf7. Exogenous exendin-4 and Fgf7 regulated an overlapping set of genes important for intestinal growth. Thus, gain and loss of GLP-1R signaling regulates gut growth and intestinal tumorigenesis.
Verbatim abstract via PubMed 25738454 ↗